



Supplemental Figures for:
Pre-treatment blood parameters predict efficacy from immunotherapy agents in early phase clinical trials
Carmen Criscitiello et al.

Figure S1. Boxplots display different levels of LDH at baseline according to the presence of visceral metastases (panel A) and previous line of therapy (panel B).



Supplemental Figures for:
Pre-treatment blood parameters predict efficacy from immunotherapy agents in early phase clinical trials
Carmen Criscitiello et al.

Figure S2. Overall response rate (ORR) and clinical benefit rate (CBR) in selected patients' subgroups. ORR according for ECOG performance status (panel A) and prior lines of therapy (panel B); CBR for age category (panel C) and LDH level (panel D).



Supplemental Figures for:
Pre-treatment blood parameters predict efficacy from immunotherapy agents in early phase clinical trials
Carmen Criscitiello et al.

Figure S3. Overall response rate (ORR) and clinical benefit rate (CBR) for monotherapy and combination therapy according to risk score (panels A and B); ORR and CBR according to the risk score (panels C and D)

